Frontiers in Oncology Seminars

When the Cancer Becomes the Enabler of an Antitumor Immune Response

February 1, 2022 

Antoni Ribas, MD, PhD, is professor of medicine, surgery, and molecular and medical pharmacology at the University of California Los Angeles (UCLA), director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA. His research is focused on laboratory and clinical studies to address primary and acquired resistance to immunotherapy and targeted therapies for melanoma, and in the development of gene-engineered adoptive T cell transfer therapies for cancer. He has been instrumental in the clinical development of several agents approved by the FDA, including the first anti-PD-1 pembrolizumab (Keytruda), two combinations of BRAF and MEK inhibitors vemurafenib (Zelboraf) and cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist), and helped develop the first CD19 CAR for lymphoma axicabtagene ciloleucel (Yescarta). He is the immediate-past president of the American Association for Cancer Research (AACR). He is an elected Fellow of the AACR Academy, the Royal Academy of Medicine of Catalonia, the American Society of Clinical Investigation, and the National Academy of Medicine.